Efficacy and Safety of Radiotherapy in Oligoprogressive HCC Following First-line PD-1 Therapy

NCT06870942 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

35

Enrollment

OTHER

Sponsor class

Conditions

HCC - Hepatocellular Carcinoma
Radiotherapy

Interventions

DRUG: Maintenance first-line treatment plus radiation therapy

Sponsor

Shanghai Zhongshan Hospital